0000000000148053

AUTHOR

Loris Roncon

showing 4 related works from this author

Management of high-risk pulmonary embolism in an "unstable medical environment": Not only a matter of hemodynamic.

2020

Diagnostic Imagingmedicine.medical_specialtybusiness.industryHemodynamicsHemodynamicsHematologymedicine.diseasePrognosisPulmonary embolismInternal medicinemedicineCardiologyHumansbusinessPulmonary EmbolismThrombosis research
researchProduct

Incidence of acute pulmonary embolism in COVID-19 patients: Systematic review and meta-analysis.

2020

Highlights • Acute pulmonary embolism (PE) is a frequent complication of COVID-19 infection. • The in-hospital incidence of acute PE among COVID-19 patients is higher in ICU patients. • Computed tomography angiography (CTPA) is infrequently performed.

medicine.medical_specialtyComputed Tomography AngiographyEpidemiology610 Medicine & healthReview Article030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicinelawInternal medicinemedicineInternal MedicineHumans030212 general & internal medicineCOVIDLungbusiness.industry10031 Clinic for AngiologyIncidenceIncidence (epidemiology)Pulmonary embolismmedicine.diseaseThrombosisIntensive care unitConfidence intervalPulmonary embolismHospitalizationIntensive Care UnitsMeta-analysismedicine.anatomical_structure2724 Internal MedicineMeta-analysisAcute DiseaseComplicationbusinessCovid-19European Journal of Internal Medicine
researchProduct

Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

2021

OBJECTIVE: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. METHODS: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping ri…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyRegistryMedDRAPeripheral edemaClinical practicePulmonary arterial hypertensionRiociguatlaw.inventionPulmonary hypertension03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicine030212 general & internal medicineAdverse effectHipertensió pulmonarRiociguatbusiness.industrymedicine.diseasePulmonary hypertensionClinical trial030228 respiratory systemPulmonary hemorrhagemedicine.symptomSafetybusinessmedicine.drug
researchProduct

Prevalence of pulmonary embolism in 127 945 autopsies performed in cancer patients in the United States between 2003 and 2019

2021

Abstract Background Pulmonary embolism (PE) is a potentially fatal disease, but data on the incidence of fatal PE in cancer patients are scant. Objective We sought to estimate the proportion of cancer patients with PE at autopsy. Methods For this retrospective cohort study, all autopsy reports of cancer patients were retrieved from PALGA: Dutch Pathology Registry and used for data extraction. The primary outcome was PE at time of autopsy, defined as any clot obstructing a pulmonary artery. The secondary outcome was venous thromboembolism, defined as the composite of thrombotic PE, deep vein thrombosis, splanchnic vein thrombosis, or internal jugular vein thrombosis. Results A total of 9571 …

medicine.medical_specialtypulmonary embolismvenous thromboembolism2720 Hematology610 Medicine & healthAutopsyautopsyNeoplasmsInternal medicineEpidemiologyPrevalencemedicineHumanscancerbusiness.industry10031 Clinic for AngiologyCancerOriginal ArticlesHematologymedicine.diseasemortalityUnited StatesPulmonary embolismTHROMBOSISOriginal ArticleepidemiologybusinessJournal of Thrombosis and Haemostasis
researchProduct